ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.

about

DNA Repair Pathway Alterations in Bladder Cancer.Evaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer.Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.

P2860

Q33607945-5863B2BA-53B7-437F-B383-0FD34E0AE142 Q33925006-903EE5C7-9A28-455F-A8D7-3F4D78AB1C3C Q49168184-CE1517A7-78EC-490F-905C-D2D36967A1DA

P2860

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.

Item

http://www.wikidata.org/entity/Q36739002

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

ATR-Chk1 signaling inhibition ...... in urothelial bladder cancer.

@ast

ATR-Chk1 signaling inhibition ...... in urothelial bladder cancer.

@en

type

Item

label

ATR-Chk1 signaling inhibition ...... in urothelial bladder cancer.

@ast

ATR-Chk1 signaling inhibition ...... in urothelial bladder cancer.

@en

prefLabel

ATR-Chk1 signaling inhibition ...... in urothelial bladder cancer.

@ast

ATR-Chk1 signaling inhibition ...... in urothelial bladder cancer.

@en

P1476

ATR-Chk1 signaling inhibition ...... y in urothelial bladder cancer

@en

P2093

Chia-Lin Lee

http://www.w3.org/2001/XMLSchema#string

Chieh-Yu Peng

http://www.w3.org/2001/XMLSchema#string

Ching-Chia Li

http://www.w3.org/2001/XMLSchema#string

Da-Yong Zhang

http://www.w3.org/2001/XMLSchema#string

Juan-Cheng Yang

http://www.w3.org/2001/XMLSchema#string

Mei-Chin Lu

http://www.w3.org/2001/XMLSchema#string

Wei-Yu Hsu

http://www.w3.org/2001/XMLSchema#string

Wen-Jeng Wu

http://www.w3.org/2001/XMLSchema#string

Yang-Chang Wu

http://www.w3.org/2001/XMLSchema#string

Yun-Hao Dai

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

Reversal of multidrug resitance by natural substances from plants

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

The resurgence of platinum-based cancer chemotherapy.

Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.

ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

P304

1947-1959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.6482

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fang-Rong Chang

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286980779

http://www.w3.org/2001/XMLSchema#string

P698

26657501

http://www.w3.org/2001/XMLSchema#string

P932

4811508

http://www.w3.org/2001/XMLSchema#string

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.

about

P2860

P2860

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932